Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $50 million gross sales price of its common shares. The common shares are listed on the Nasdaq Global Market under the symbol “AFMD.”

Based in Heidelberg, Germany, Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells.

The Davis Polk capital markets team included partner Derek Dostal and associate Dan Gibbons. Partner Patrick E. Sigmon provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock. All members of the Davis Polk team are based in the New York office.

Copy link to share post